Akt deficiency impairs normal cell proliferation and suppresses oncogenesis in a p53-independent and mTORC1-dependent manner
- 1 October 2006
- journal article
- research article
- Published by Elsevier BV in Cancer Cell
- Vol. 10 (4), 269-280
- https://doi.org/10.1016/j.ccr.2006.08.022
Abstract
No abstract availableThis publication has 41 references indexed in Scilit:
- The deficiency ofAkt1is sufficient to suppress tumor development inPten+/−miceGenes & Development, 2006
- Akt Activates the Mammalian Target of Rapamycin by Regulating Cellular ATP Level and AMPK ActivityPublished by Elsevier BV ,2005
- mTOR Controls Cell Cycle Progression through Its Cell Growth Effectors S6K1 and 4E-BP1/Eukaryotic Translation Initiation Factor 4EMolecular and Cellular Biology, 2004
- AKT Activity Determines Sensitivity to Mammalian Target of Rapamycin (mTOR) Inhibitors by Regulating Cyclin D1 and c-myc ExpressionPublished by Elsevier BV ,2004
- Targeting RAS signalling pathways in cancer therapyNature Reviews Cancer, 2003
- Growth retardation and increased apoptosis in mice with homozygous disruption of the akt1 geneGenes & Development, 2001
- p70S6 kinase signals cell survival as well as growth, inactivating the pro-apoptotic molecule BADProceedings of the National Academy of Sciences of the United States of America, 2001
- The Akt kinase: Molecular determinants of oncogenicityProceedings of the National Academy of Sciences of the United States of America, 1998
- Pten is essential for embryonic development and tumour suppressionNature Genetics, 1998
- 4E-BP1, a repressor of mRNA translation, is phosphorylated and inactivated by the Akt(PKB) signaling pathwayGenes & Development, 1998